27 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/fda-approves-gamifant-emapalumab-lzsg-as-first-ever-treatment-for-adults-and-children-with-macrophage-activation-syndrome-in-stills-disease-302493712.html
19 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sobi-announces-a-new-research-collaboration-on-the-development-of-gamifant-emapalumab-in-sepsis-which-is-to-be-presented-at-the-isicem-congress-302405595.html
07 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/07/2976470/0/en/Sobi-to-present-new-data-across-its-immunology-portfolio-at-the-ACR-Convergence-2024.html
30 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/new-data-for-emapalumab-in-the-treatment-of-macrophage-activation-syndrome-to-be-presented-at-the-acr-conference-302291213.html
24 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/24/2888151/0/en/Sobi-Receives-US-FDA-Fast-Track-Designation-for-Emapalumab-lzsg-being-investigated-in-Macrophage-Activation-Syndrome.html
04 Apr 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/04/04/2640441/0/en/Annals-of-Rheumatic-Diseases-Publishes-Results-from-Phase-2-Study-of-emapalumab-in-Patients-with-Secondary-HLH-Macrophage-Activation-Syndrome.html